|
US4324893A
(en)
|
1979-04-18 |
1982-04-13 |
American Home Products Corporation |
4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
|
|
UY27304A1
(es)
|
2001-05-24 |
2002-12-31 |
Avanir Pharmaceuticals |
Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
|
|
CA2489560A1
(en)
|
2002-06-27 |
2004-01-08 |
Schering Aktiengesellschaft |
Substituted quinoline ccr5 receptor antagonists
|
|
GB0230018D0
(en)
|
2002-12-23 |
2003-01-29 |
Syngenta Ltd |
Fungicides
|
|
TW200418829A
(en)
|
2003-02-14 |
2004-10-01 |
Avanir Pharmaceutics |
Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
|
|
TWI289141B
(en)
|
2003-03-11 |
2007-11-01 |
Hoffmann La Roche F. Ag. |
Quinolinone derivatives and uses thereof
|
|
WO2004087880A2
(en)
|
2003-03-26 |
2004-10-14 |
Bayer Pharmaceuticals Corporation |
Compounds and their use to treat diabetes and related disorders
|
|
GB0316915D0
(en)
|
2003-07-18 |
2003-08-20 |
Glaxo Group Ltd |
Compounds
|
|
CA2533626A1
(en)
|
2003-07-22 |
2005-02-03 |
Janssen Pharmaceutica, N.V. |
Quinolinone derivatives as inhibitors of c-fms kinase
|
|
JP2007503388A
(ja)
|
2003-08-22 |
2007-02-22 |
アバニール・ファーマシューティカルズ |
マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
|
|
US7381401B2
(en)
*
|
2004-01-08 |
2008-06-03 |
The University Of Chicago |
T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール,インク. |
Gitr結合分子およびその使用
|
|
DK1879573T3
(da)
|
2005-05-10 |
2013-02-25 |
Incyte Corp |
Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
GB0605689D0
(en)
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic compounds
|
|
JP5422204B2
(ja)
*
|
2006-03-30 |
2014-02-19 |
国立大学法人 千葉大学 |
DGKα阻害剤を含有する抗癌剤
|
|
JP2007308402A
(ja)
|
2006-05-17 |
2007-11-29 |
Sumitomo Chemical Co Ltd |
シンナモイル化合物及びその用途
|
|
JP2007308441A
(ja)
|
2006-05-22 |
2007-11-29 |
Sumitomo Chemical Co Ltd |
含複素環化合物及びその用途
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
CA2663057C
(en)
|
2006-09-19 |
2015-12-08 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
TW200829554A
(en)
|
2006-09-29 |
2008-07-16 |
Tibotec Pharm Ltd |
Quinolinone derivatives
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
WO2009073620A2
(en)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics |
Ido inhibitors
|
|
EP2296789A1
(fr)
|
2008-05-29 |
2011-03-23 |
Saint-Gobain Centre de Recherches et d'Etudes Européen |
Structure en nid d'abeille a base de titanate d'aluminium
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010042489A2
(en)
|
2008-10-06 |
2010-04-15 |
Emory University |
Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
US20110319416A1
(en)
|
2009-01-28 |
2011-12-29 |
Emory University |
Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
|
|
IN2015DN02826A
(cg-RX-API-DMAC7.html)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
|
EP2493862B1
(en)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Imidazole derivatives as ido inhibitors
|
|
DK2510010T3
(en)
|
2009-12-10 |
2015-12-14 |
Hoffmann La Roche |
Antibodies that bind to human CSF1R extracellular domain 4 and their use
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
EP3943154A1
(en)
|
2010-05-04 |
2022-01-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
|
WO2012009649A1
(en)
*
|
2010-07-16 |
2012-01-19 |
Anderson Gaweco |
Mif inhibitors and their uses
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
US9133164B2
(en)
|
2011-04-13 |
2015-09-15 |
Innov88 Llc |
MIF inhibitors and their uses
|
|
NO2694640T3
(cg-RX-API-DMAC7.html)
|
2011-04-15 |
2018-03-17 |
|
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
MX2014008961A
(es)
|
2012-02-06 |
2014-10-14 |
Genentech Inc |
Composiciones y metodos para utilizar inhibidores de csf1r.
|
|
US9006257B2
(en)
|
2012-02-09 |
2015-04-14 |
Glenmark Pharmaceuticals S.A. |
Bicyclic compounds as mPGES-1 inhibitors
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
MX2021006804A
(es)
|
2015-12-17 |
2023-01-13 |
Merck Patent Gmbh |
Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
|
|
WO2017177037A1
(en)
|
2016-04-06 |
2017-10-12 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
|
CR20190338A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso
|
|
GB201700814D0
(en)
|
2017-01-17 |
2017-03-01 |
Liverpool School Tropical Medicine |
Compounds
|
|
UA127968C2
(uk)
|
2017-05-22 |
2024-02-28 |
Емджен Інк. |
Інгібітори g12c kras і способи їх застосування
|
|
US12187687B2
(en)
|
2017-06-26 |
2025-01-07 |
University Of Virginia Patent Foundation |
Compositions and uses thereof
|
|
CN109575016B
(zh)
|
2017-09-28 |
2022-01-04 |
药捷安康(南京)科技股份有限公司 |
Pde9抑制剂及其用途
|
|
CN112654621B
(zh)
*
|
2018-06-27 |
2024-05-14 |
百时美施贵宝公司 |
可作为t细胞活化剂的经取代萘啶酮化合物
|
|
SG11202012973RA
(en)
|
2018-06-27 |
2021-01-28 |
Bristol Myers Squibb Co |
Naphthyridinone compounds useful as t cell activators
|
|
CN111471059B
(zh)
*
|
2019-01-23 |
2022-12-02 |
药捷安康(南京)科技股份有限公司 |
Pde9抑制剂及其用途
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
WO2021105115A1
(en)
|
2019-11-28 |
2021-06-03 |
Bayer Aktiengesellschaft |
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
|
|
US12478621B2
(en)
|
2019-11-28 |
2025-11-25 |
Deutsches Krebsforschungszentrum |
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
|
|
EP4065584A1
(en)
|
2019-11-28 |
2022-10-05 |
Bayer Aktiengesellschaft |
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
|